TYROSINE KINASE INHIBITORS AND PREGNANCY

Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti
  • Elisabetta Abruzzese
    Hematology, S. Eugenio Hospital, Tor Vergata University Piazzale dell’Umanesimo 10 00144 Rome, Italy, Italy | elisabetta.abruzzese@uniroma2.it
  • Malgorzata Monika Trawinska
    Affiliation not present
  • Paolo De Fabritiis
    Affiliation not present
  • Alessio Pio Perrotti
    Affiliation not present

Abstract

The management of patients with chronic myeloid leukemia (CML) during pregnancy has became recently a matter of continuous debate.  The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of CML patients.  Patients diagnosed in chronic phase can reasonably expect many years of excellent disease control and good quality of life, as well as a normal life expectancy.  This fact has come the necessity to address issues relating to fertility and pregnancy. Physicians are not infrequently being asked for advice regarding the need for, and or the appropriateness of, stopping treatment in order to conceive. In this report we will review the data published in terms of fertility, conception, pregnancy, pregnancy outcome and illness control for all the approved TKIs, as well as suggest how to manage a planned and/or unplanned pregnancy.

Full Text:

PDF
HTML
Submitted: 2014-07-21 14:05:14
Published: 2014-04-07 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
1377

Views:
PDF
457
HTML
2282

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy